{"organizations": [], "uuid": "43e2f31abcaf01d3e6c4d5f8aa3c107922ebc85c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180223.html", "section_title": "Archive News &amp; Video for Friday, 23 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-swedish-orphan-biovitrum-says-rece/brief-swedish-orphan-biovitrum-says-receives-positive-opinion-from-chmp-on-anakira-idUSFWN1QD1BZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Swedish Orphan Biovitrum says receives positive opinion from CHMP on Anakira", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.711, "site_type": "news", "published": "2018-02-23T23:00:00.000+02:00", "replies_count": 0, "uuid": "43e2f31abcaf01d3e6c4d5f8aa3c107922ebc85c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-swedish-orphan-biovitrum-says-rece/brief-swedish-orphan-biovitrum-says-receives-positive-opinion-from-chmp-on-anakira-idUSFWN1QD1BZ", "ord_in_thread": 0, "title": "BRIEF-Swedish Orphan Biovitrum says receives positive opinion from CHMP on Anakira", "locations": [], "entities": {"persons": [{"name": "biovitrum", "sentiment": "negative"}, {"name": "johan sennero", "sentiment": "none"}], "locations": [{"name": "anakinra", "sentiment": "none"}], "organizations": [{"name": "committee for medicinal products", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "orphan biovitrum ab", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "european commission", "sentiment": "none"}, {"name": "european medicines agency", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 23 (Reuters) - Swedish Orphan Biovitrum Ab (Publ) says:\n* The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Anakinra for the treatment of Stillâ€™s disease.\n* The opinion is now referred to the European Commission for a decision. Source text for Eikon: Further company coverage: (Reporting By Johan Sennero)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-23T23:00:00.000+02:00", "crawled": "2018-02-24T13:38:13.029+02:00", "highlightTitle": ""}